Skip to main content
. Author manuscript; available in PMC: 2013 Sep 27.
Published in final edited form as: Am J Transplant. 2007 Feb 7;7(5):1055–1061. doi: 10.1111/j.1600-6143.2006.01703.x

Figure 1. Posttransplant course (serum creatinine levels) of recipients in Groups SKBMT, A, B and C.

Figure 1

Red solid lines and black dashed lines indicate creatinine changes in the tolerant recipients and rejectors, respectively. SKBMT: All eight recipients of SKBMT developed mixed chimerism and 7 of 8 survived long term without acute rejection with four of them acquired allograft tolerance. Group A: All four recipients in Group A failed to develop mixed chimerism and rejected their kidney allografts. Group B: One recipient that developed limited chimerism survived long term, but eventually developed chronic rejection and was euthanized due to kidney failure on day 703 after DBMT. Two recipients failed to develop chimerism and rejected their kidney allograft on days 64 and 16. Group C: Three recipients (red lines) in Group C successfully developed mixed chimerism and have never developed rejection with two recipients currently surviving at 1.8 and 2.8 years after DBMT with normal kidney function. The other (red squares) died on day 67 due to refractory ascites caused by right atrial thrombus, which may be attributed to side effects of anti-CD154 antibody at the time of DBMT. Two recipients failed to develop mixed chimerism and rejected their allograft on days 61 and 35.